Literature DB >> 19363685

MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility.

Arnoldo Aquino-Galvez1, Martha Pérez-Rodríguez, Angel Camarena, Ramces Falfan-Valencia, Víctor Ruiz, Martha Montaño, Lourdes Barrera, Isabel Sada-Ovalle, Remedios Ramírez, Julio Granados, Annie Pardo, Moisés Selman.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disorder of unknown etiology. IPF is likely the result of complex interrelationships between environmental and host factors, although the genetic risk factors are presently uncertain. Because we have found that some MHC polymorphisms confer susceptibility to IPF, in the present study we aimed to evaluate the role of the MHC class I chain-related gene A (MICA) in the risk of developing the disease. MICA molecular typing was done by reference strand mediated conformation analysis in a cohort of 80 IPF patients and 201 controls. In addition, the lung cellular source of the protein was examined by immunohistochemistry, the expression of the MICA receptor NKG2D in lung cells by flow cytometry and soluble MICA by ELISA. A significant increase of MICA*001 was observed in the IPF cohort (OR = 2.91, 95% CI = 1.04-8.25; pC = 0.03). Likewise, the frequency of the MICA*001/*00201 genotype was significantly increased in patients with IPF compared with the healthy controls (OR = 4.72, 95% CI = 1.15-22.51; pC = 0.01). Strong immunoreactive MICA staining was localized in alveolar epithelial cells and fibroblasts from IPF lungs while control lungs were negative. Soluble MICA was detected in 35% of IPF patients compared with 12% of control subjects (P = 0.0007). The expression of NKG2D was significantly decreased in gammadelta T cells and natural killer cells obtained from IPF lungs. These findings indicate that MICA polymorphisms and abnormal expression of the MICA receptor NKG2D might contribute to IPF susceptibility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363685     DOI: 10.1007/s00439-009-0666-1

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  51 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.

Authors:  A L Katzenstein; J L Myers
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

Review 3.  Evolving concepts of apoptosis in idiopathic pulmonary fibrosis.

Authors:  Victor J Thannickal; Jeffrey C Horowitz
Journal:  Proc Am Thorac Soc       Date:  2006-06

4.  Gelatinases A and B are up-regulated in rat lungs by subacute hyperoxia: pathogenetic implications.

Authors:  A Pardo; R Barrios; V Maldonado; J Meléndez; J Pérez; V Ruiz; L Segura-Valdez; J I Sznajder; M Selman
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 5.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

6.  BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.

Authors:  Nicolas Boissel; Delphine Rea; Vannary Tieng; Nicolas Dulphy; Manuel Brun; Jean-Michel Cayuela; Philippe Rousselot; Ryad Tamouza; Philippe Le Bouteiller; François-Xavier Mahon; Alexander Steinle; Dominique Charron; Hervé Dombret; Antoine Toubert
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma.

Authors:  Shigehiro Tamaki; Masayoshi Kawakami; Yasutsugu Yamanaka; Hiroyuki Shimomura; Yuichiro Imai; Jun-ichi Ishida; Kazuhiko Yamamoto; Akiko Ishitani; Katsuhiko Hatake; Tadaaki Kirita
Journal:  Clin Immunol       Date:  2008-10-23       Impact factor: 3.969

8.  Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients.

Authors:  Marie-Noëlle Peraldi; Jeannig Berrou; Nicolas Dulphy; Alexandre Seidowsky; Philippe Haas; Nicolas Boissel; Fabien Metivier; Christine Randoux; Niloufar Kossari; Alain Guérin; Sylvie Geffroy; Guy Delavaud; Viviana Marin-Esteban; Denis Glotz; Dominique Charron; Antoine Toubert
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

9.  Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.

Authors:  Lizzia Raffaghello; Ignazia Prigione; Irma Airoldi; Marta Camoriano; Isabella Levreri; Claudio Gambini; Daniela Pende; Alexander Steinle; Soldano Ferrone; Vito Pistoia
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

10.  Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.

Authors:  Moisés Selman; Guillermo Carrillo; Andrea Estrada; Mayra Mejia; Carina Becerril; José Cisneros; Miguel Gaxiola; Rogelio Pérez-Padilla; Carmen Navarro; Thomas Richards; James Dauber; Talmadge E King; Annie Pardo; Naftali Kaminski
Journal:  PLoS One       Date:  2007-05-30       Impact factor: 3.240

View more
  21 in total

1.  Association of major histocompatibility complex class 1 chain-related gene a dimorphism with type 1 diabetes and latent autoimmune diabetes in adults in the Algerian population.

Authors:  Rachida Raache; Khadidja Belanteur; Habiba Amroun; Amel Benyahia; Amel Heniche; Malha Azzouz; Safia Mimouni; Thibaud Gervais; Dominique Latinne; Aissa Boudiba; Nabila Attal; Mohamed Cherif Abbadi
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

2.  NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline.

Authors:  Andrew R Osterburg; Rebecca L Nelson; Benyamin Z Yaniv; Rachel Foot; Walter Rf Donica; Madison A Nashu; Huan Liu; Kathryn A Wikenheiser-Brokamp; Joel Moss; Nishant Gupta; Francis X McCormack; Michael T Borchers
Journal:  JCI Insight       Date:  2016-10-06

3.  Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation.

Authors:  Nataraju Angaswamy; Deepti Saini; Sabarinathan Ramachandran; Dilip S Nath; Donna Phelan; Ramsey Hachem; Elbert Trulock; G Alexander Patterson; T Mohanakumar
Journal:  Hum Immunol       Date:  2010-03-16       Impact factor: 2.850

Review 4.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis.

Authors:  Qiang Ding; Tracy Luckhardt; Louise Hecker; Yong Zhou; Gang Liu; Veena B Antony; Joao deAndrade; Victor J Thannickal
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 5.  Natural killer cells in infection and inflammation of the lung.

Authors:  Fiona J Culley
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

6.  Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury.

Authors:  Daniel R Calabrese; Emily Aminian; Benat Mallavia; Fengchun Liu; Simon J Cleary; Oscar A Aguilar; Ping Wang; Jonathan P Singer; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Mary Nakamura; Lewis L Lanier; Mark R Looney; John R Greenland
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

Review 7.  Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight).

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-04-29

8.  Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells.

Authors:  Yong Huang; Justin M Oldham; Shwu-Fan Ma; Avraham Unterman; Shu-Yi Liao; Andrew J Barros; Catherine A Bonham; John S Kim; Rekha Vij; Ayodeji Adegunsoye; Mary E Strek; Philip L Molyneaux; Toby M Maher; Jose D Herazo-Maya; Naftali Kaminski; Bethany B Moore; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2021-07-15       Impact factor: 30.528

9.  Genome sequencing of idiopathic pulmonary fibrosis in conjunction with a medical school human anatomy course.

Authors:  Akash Kumar; Max Dougherty; Gregory M Findlay; Madeleine Geisheker; Jason Klein; John Lazar; Heather Machkovech; Jesse Resnick; Rebecca Resnick; Alexander I Salter; Faezeh Talebi-Liasi; Christopher Arakawa; Jacob Baudin; Andrew Bogaard; Rebecca Salesky; Qian Zhou; Kelly Smith; John I Clark; Jay Shendure; Marshall S Horwitz
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

10.  Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Authors:  Tasha E Fingerlin; Weiming Zhang; Ivana V Yang; Hannah C Ainsworth; Pamela H Russell; Rachel Z Blumhagen; Marvin I Schwarz; Kevin K Brown; Mark P Steele; James E Loyd; Gregory P Cosgrove; David A Lynch; Steve Groshong; Harold R Collard; Paul J Wolters; Williamson Z Bradford; Karl Kossen; Scott D Seiwert; Roland M du Bois; Christine Kim Garcia; Megan S Devine; Gunnar Gudmundsson; Helgi J Isaksson; Naftali Kaminski; Yingze Zhang; Kevin F Gibson; Lisa H Lancaster; Toby M Maher; Philip L Molyneaux; Athol U Wells; Miriam F Moffatt; Moises Selman; Annie Pardo; Dong Soon Kim; James D Crapo; Barry J Make; Elizabeth A Regan; Dinesha S Walek; Jerry J Daniel; Yoichiro Kamatani; Diana Zelenika; Elissa Murphy; Keith Smith; David McKean; Brent S Pedersen; Janet Talbert; Julia Powers; Cheryl R Markin; Kenneth B Beckman; Mark Lathrop; Brian Freed; Carl D Langefeld; David A Schwartz
Journal:  BMC Genet       Date:  2016-06-07       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.